Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s the sound of a time bomb set by J&E few years ago. When will the bomb go off?
I have not settled yet which lottery I'd prefer to win: Mega Millions or Powerball. Meantime, I continue to hold to my ADXS shares as a lottery ticket. I hope my chances of winning the latter are somewhat higher than the former tickets. We all break the cancer code and match those numbers with the mutated gene codes to strike the gold.
That is a ridiculous statement.
Did you mean the competition valuation should help improve our valuation? It might have helped once during Adro IPO run up, but not since.
The sad reality is that the competition can leave us behind thus making us less valuable and less desirable. Over abundance of the checkpoint combo trials has made the landscape very challenging. It led the big boys off the hook to sign lucrative contracts with cash upfront. They just supply a drug. For free. And wait for data. What makes you think that similar shift is not occurring in the neoantigen therapy area?
Gritstone Oncology partners with BMY to develop personalized neoantigen therapy
https://www.businesswire.com/news/home/20180719005194/en/
The competition doesn’t stand still ...
No that bad compared to those who predicted $20 after the hold is lifted.
It's likely done by a HFT suppression department of Amgen, division of Dark Forces to Stop an Endless Flow of Cash from Selling Non-Cures.
How did most of us fail to see that? I take my hat off to bow to your superior intellect...
@wmtgreeter
Methinks we go to da moon, orbit it twice and come back to the Earth safely. Landing will be hard, not sure if the spacecraft could survive it.
I think it's about time that someone starts a buyout speculation...
Why not? Remember when the buyout conjectures erupted when the company went silent last time?
Feel free to connect the dots.
There should be a checkbox in any CEO application:" Do you have any ADD symptoms?", particularly for companies like Advaxis.
Did DOC have clear signs of ADD? How did we miss that? He also might have had a severe form of RSUtitis.
will be a CR
Controlled Retraction of stock?
Miracles happen. Cellectar (CLRB) is up almost 1,750% this morning on great clinical data.
https://finance.yahoo.com/news/cellectar-reports-94-reduction-overall-120000856.html
Can preliminary NEO data send our stock soaring like that?
Much shorter or more precise corporate presentation: 22 pages vs 38 pages back in March.
I think they want to ride a HOT horse:
HOT:
? First IND submitted in June 2018 (NSCLC); second to be submitted by end 2018 (prostate)
? 2 additional INDs planned by end of 2019, selected from breast, colorectal, bladder, ovarian, head-and-neck cancers
It would be great to present the NEO clinical data at ASCO-2019. If the results are great, they have a plenty of time to submit an (latebreaking) abstract by February/March '19. ASCO is by far the best podium to showcase the clinical data.
I'd be leery about cranking up that PR machine: we had that issue during the DOC tenure -- 1 PR per 10 days, on average. Fluff PRs are nothing but but a red fabric for shorts.
I'd like to see only PRs with some material substance. I think the news comes when it comes, and we have no influence over it. Patience.
PS. I wish I had a GED in Inorganic Chemistry like Chemist823 to be that smart and sell some shares during the spike to $2.40 in the PM last Friday.
@wmtgreeter
They're pretty much a bunch of locusts: get to the green pasture, destroy it completely in a short period of time, and then to the next green field.
Remember ImClone -> Advaxis ->Oncosec.
An endless life cycle of vermins...
We also have a TOM AWARD winner, a DAN AWARD winner , and a we are halfway to a KEN AWARD trophy presentation ceremony. The award includes a Las Vegas trip, followed by a Wen restaurant dinner with Sushi and Sapporo served by trays and gallons at the expense of the retired hygienist.
I think your mood changes quicker than a wind direction at the top of Mt Everest. Remember you mentally parted with your 120 shares? Enjoy your trip to a local Walmart!
@wmtgreeter
Can we say $4.746B by 2035? Too aggressive time line?
I’m also puzzled why Ken telegraphed he’d discontinue AXAL if he’s unable to sell or partner it within a relatively short period of time. The market currently puts almost a zero value on it due to that strategy as the probability of successful continuation leading to a drug approval is virtually nil. If Ken can find a partner to shoulder the trials, then the valuation will change. That would be a huge surprise.
If Ken used this announcement as a negotiation strategy, he is likely going to fail. Big Pharma sees this through as Ken tries to negotiate from the position of the weakness. Maybe, Ken was too honest to signal what is inevitable, we shall see.
Lots of churning, shares bought and sold by HFT algos.
Someone made a killing by selling short in the PM in $2.20-$2.40 range to cover at $1.35-$1.45 range.
PS. I had hoped to hold $1.50 line in the sands, but alas...
It's HFT, per well informed sources.
Hey, maybe Blew's buddy can shed some lights on today's trading. He keeps his employees up to date with respect to the machinations behind the curtains. Could he a puppet master himself? You never know...
If today was any indicator, the bids will be above $4.87 in the premarket should any meaningful news hit the wires. As for the volume will be exceeding 1/2 of the float.
@wmtgreeter, making uneducated wild-a$$ guesses since 18xx.
The company will be sold this coming Monday.
Everything points towards that happening.
1. Hold lifted;
2. No feedback to requests from the company;
3. Volume is extraordinary;
4. Announcement made Friday the 13th, in the morning;
5. Big Bernie is back;
6. Take your pick.
I have paraskevidekatriaphobia as I fear Friday 13th, LOL.
I hope we get a meaningful pop, but I don;t count on it. Too many trapped shareholders will be selling into some strength today trying to get out. We shall see if we close at $1.50 or over.
I'd appreciate it if you could write some short article summarizing recent developments and outline your vision of the future for Advaxis. I think the landscape has changed significantly.
@wmtgreeter and a proud reader of SA articles by Zach Hartman.
It took 126 freaking days to lift this freaking HOLD!
Glad it's over!
Good luck to all who survived this slaughter!
We are not out of woods yet, but I saw a glimpse of a sunshine this morning. My eyes hurt...
Genosse Oliver:
You have to keep your risks manageable. This is a very risky biotech. We all have learned the lesson hard way.
Very odd way of communicating with the shareholders...
Recall a perplexing interview with Sara Bonstein back in January that raised eyebrows, an then she's gone.
Now Petit referring to a SA article written not by Hovacre (Z. Hartman) but by InovioRulez. The latter author is known to have a very strong bias to one or the other side, and quite frankly is not as deep as ZH. I've read some of his articles, and honestly, there's not much of a substance not what an investor would want to find.
The best way to communicate for the management would have been to have a brief conference call after the announcement about pulling MAA application and explain the path forward. What cash burns are, what cash needs are, how they are going to address the issue, and explain AXAL stalemate. Nothing of that has happened. This is what differentiates a good management from a bad one.
Just bought 6K ADXS options @1.2
In a race to the bottom, we are ahead of ONCS: $1.17 vs $1.27. We will cross the $1-finish line first! We'll beat DOC by his own weapon.
After all, I must admit that probably infamous Pearson article was correct characterizing ADXS as a fraud.
https://seekingalpha.com/article/2836026-advaxis-heavily-promoted-and-misleading-investors
The real seller here is likely Adage who got in this equity for a LM platform, long before NEO. Since the AXAL is going to be canned, Adage maybe looking a way out of this equity. Equally possible that some of the recent buyers during the secondary are getting out. This is also exacerbated by the retail bailing completely.
Advaxis management needs to wake up!
I believe we must start sending emails and make phone calls to the company, to the CEO, to the BOD chairman demanding a resignation of Sidransky.
If no deal is in work, they won't be able to get anything done by the end of summer. The markets are signaling nothing is close to be finalized.
Tony's tenure was an utter failure. Wow!
This BOD Chairman must resign immediately!
This stock is just so toxic...
When do we hit 50 brother?
This is from DOC's LinkedIn page. You can't make this shit up!
CEO and Director
Company NameAdvaxis, Inc.
Dates EmployedJan 2012 – Jul 2017 Employment Duration5 yrs 7 mos
LocationPrincton, New Jersey
As CEO of Advaxis, uplisted onto NASDAQ and, in five years, transformed the company into a well-funded, well-staffed, leading cancer immunotherapy company with collaborations with Amgen Inc., Merck & Co., Bristol Myers Squib and AstraZeneca.
I've seen many open market buys by other management teams. Although there's a correlation of that event with a future share price appreciation, the correlation coefficient is not 1. Some insider buys are just insider buys to prop the share price, with nothing to follow. Even insider sells are not 100% indicative of a bad news coming, not necessarily.
With this management, I do not know what to expect. Hard to read, and it's very frustrating. So, just I'm going sit in a Lotus position and will be a simple observer.
I agree, it's a capitulation v2.0. Many shareholders bailed within the past year at much higher prices. Now, it's the next wave. Will it be Capitulation v3.0?
As for a positive indicator, it could be, I do not know. J&E was touting about a share grab. That was long time ago. Obviously, she was either wrong or, more likely, masquerading as a prophet, a sheep in a wolf's skin. It's hard to spin this as a positive as the share price collapses while we watch. I am just expecting some positive news/development soon enough, while mentally preparing to have a 100% loss in this equity. C'est la vie!